Background
==========

We demonstrated in a phase 1 trial that an immunotherapy (AGS-004) consisting of a monocyte-derived dendritic cells (DC) and RNA encoding autologous HIV antigens (Gag, Nef, Rev, Vpr) derived from the patient\'s own pre-ART plasma induced immunogenicity in most patients. Based on these results a multicenter phase 2 trial was implemented to assess the safety and proportion of patients demonstrating viral load (VL) \< 1000, \< 5000 and \< 10,000 copies/ml during the 12 week ART structured treatment interruption (STI).

Methods
=======

Subjects on their initial ART regimen with VL \< 50 copies/ml, CD4 \> 450 cells/μl, CD4 nadir \> 200 cells/μl and a pre-ART VL \> 10,000 to 500,000 copies/ml were eligible. The treatment consists of 4 intradermal AGS-004 doses administered monthly in combination with ART followed by two more doses during the 12 week STI. Subjects who participated in the phase 1 study were included and received a second cycle of AGS-004. Subjects may continue AGS-004 booster administration if VL remains \< 10,000 copies/ml.

Results
=======

33 subjects were enrolled from 11 Canadian sites, and AGS-004 successfully manufactured and administered to 21 subjects. 9 subjects have successfully completed 12 weeks of STI. The immunotherapy related AEs were Grade 1 or 2 flu-like, GI symptoms, fatigue, and injection site reactions. During the STI, no reports of autoimmunity or AIDS defining events were observed. After an initial viral rebound, 4 out of 9 subjects had \> 2 instances of VL measures \< 1000 copies/mL when assessed every 2 weeks during the STI. At week 12 of STI 5 subjects had viral loads \< 10,000 copies/ml with CD4 \> 350 cells/μl including 4 subjects with viral loads \< 5000 copies/ml.

Conclusion
==========

Results from this phase 2 autologous immunotherapy trial demonstrated that this therapy is safe and induced partial control of VL when compared to pre-ART VL during the 12-week STI.
